Teaching

Invited Talks/Workshops/Symposia:

1. “You Have a Great Technology…Now What?”- ASGCT, Baltimore MD, 5/11/24
2. “Recent advancements that expand viral vector delivery applications”- ASGCT, Baltimore MD, 5/11/24
3. “Safety and Efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D”- ARVO, Seattle, WA. 5/5/24- *Symposium presentation
4. “IND-enabling Studies to Support the Clinical Development of ATSN-201, a Subretinally Delivered, Laterally Spreading Gene Replacement Therapy for X-Linked Retinoschisis (XLRS)” – FFB Gene Therapy Innovation Summit, Seattle, WA. 5/3/24
5. “Unlocking the Power of Delivery: Advancing Gene Therapy with Innovative Platforms” – FFB “Investing in Cures Summit” Scottsdale, AZ. 3/8/24
6. “Gene Therapy for GUCY2D LCA1”- Hope in Focus LCA Family Conference, 6/23/23
7. Foundation Fighting Blindness “Insights Forum”- 5/31/23
8. Foundation Fighting Blindness “Investing in Cures Summit”- 2/10/23
9. Hope in Focus “Let’s Chat About It”- 10/27/22
10. University of Florida’s Office of Technology and Licensing- “Fireside Chat” 10/26/22
11. “Exploring the Laterally Spreading AAV.SPR Capsid for Treatment of Inherited Retinal Diseases”- Gene Therapy for Ophthalmic Disorders. 9/14/22
12. “Ocular Gene Therapy: Challenges and Opportunities”- SEMM Technological Roundtable ‘Clinical in vivo gene therapy with AAV vectors: now and beyond’. 12/17/21 (virtual)
13. “Developing a Gene Therapy for Vision Loss Associated with Friedreich’s Ataxia” Gene therapy: advances and perspectives and moving into the clinic. Center for Genetic Engineering and Maintenance (CenGem), Brunel University London. 11/26/21 (virtual)
14. “Gene Therapy for GUCY2D-Leber congenital amaurosis, from Bench to Bedside”- 2021 NIH Neuroscience Seminar Series, 9/27/21 (virtual)
15. “Gene Therapy for GUCY2D Leber congenital amaurosis”- Hanson Wade Gene Therapy for Ophthalmic Disorders Meeting, 9/22/21 (virtual)
16. “Development of a Dual AAV Vector- based Gene Therapy for MYO7A- associated USH1B”- Foundation Fighting Blindness USH1B Workshop, 9/13/21 (virtual)
17. “Developing a Gene Therapy for Vision Loss Associated with Friedreich’s Ataxia”. FARA Research Symposium, 9/14/21 (virtual)
18. “Night for Sight”- Foundation Fighting Blindness, 6/8/21 (virtual)
19. “Gene therapy for recessive and dominant retinal disease”. 2020 Midwest Eye Research Conference (MERS)- Medical College of Wisconsin, Milwaukee, WI, 7/31/20 *Keynote speech
20. “What’s next in Gene Therapy”- FFB VISIONS, 6/25/20 (virtual)
21. “Gene Therapy for Photoreceptor-Mediated Disease”- Tulane University, New Orleans, LA, 12/6/19
22. “Gene Therapy for Photoreceptor-Mediated Disease”- TIGEM (Telethon Institute of Genetics and Medicine). Naples, Italy, 9/19/19
23. “Gene Therapy for Photoreceptor-Mediated Disease”- University of Alabama at Birmingham, 2/11/19, Birmingham, AL
24. “Gene therapy in retina”- Identifying Treatments for Taste and Smell Disorders, 11/14/18, Philadelphia, PA
25. “Gene Therapy for Photoreceptor-Mediated Disease”- Storm Eye Institute, Medical University of South Carolina. Charleston, SC, 9/27/18
26. “Leber congenital Amaurosis”- Foundation Fighting Blindness VISIONS conference, San Diego, CA, 6/23/18
27. “Gene Therapies”- Foundation Fighting Blindness VISIONS conference, San Diego, CA, 6/22/18
28. “AAV Vectors in the Eye”- American Society of Gene and Cell Therapy, Chicago, IL, 5-19-18
29. “Gene Therapy 101”- “Brave New World: Gene Therapy for Inherited Retinal Diseases” symposium. Institute for Continuing Healthcare Education, Honolulu, HI 4-28-18
30. “Development of a gene therapy for biallelic mutations in GUCY2D”. Innovation Summit for Retinal Cell and Gene Therapy, Honolulu, HI 4-26-18
31. “Gene Therapy for Photoreceptor-Mediated Disease”- Department of Molecular Genetics and Microbiology Research Seminar Series, University of Florida, 3-13-18
32. “Gene Therapy for Photoreceptor-Mediated Disease”- Department of Pharmacology and Therapeutics Research Seminar Series, University of Florida, 2-21-18
33. “Gene Delivery to the Retina: Current and Emerging Technologies”. State University of New York at Buffalo, 2-6-18
34. “Gene Therapy for Photoreceptor-Mediated Disease”- North Texas Eye Research Institute, 11-6-17
35. “Gene and Drug Therapies”- Foundation Fighting Blindness Investing in Cures Summit. Chicago, IL. 9-15-17
36. “Gene Therapy 101 and Current Applications”- Achromacorp Conference 7-1-2017, Milwaukee, WI
37. “Identification of AAV capsid variants with enhanced retinal transduction following screening in non-human primate”. 4th Annual Retinal Cell and Gene Therapy Innovation Summit. Baltimore, MD, May 5^th, 2017
38. “Gene Therapy for Photoreceptor-Mediated Disease”- Children’s Research Hospital of Philadelphia, University of Pennsylvania. April 24^th, 2017
39. “USH talk”- Usher Coalition- April 15^th, 2017
40. “UF Preeminence Report”- College of Medicine Leadership Council meeting. March 17^th, 2017
41. “Coffee Talk”, University of Florida’s Office of Research. March 2^nd, 2017
42. “Gene Therapy for USH1B- Two Steps Forward, One Step Back”- January 23^rd, 2017. UF Center for Vision Research Annual Symposium
43. “Gene Therapy for GUCY2D-LCA1”- Editas Medicine- October 3rd, 2016
44. “Retinal Transduction by AAV in non-human primate”- AGTC/Synpromics September 15^th, 2016
45. “Gene Delivery to the Retina: Current and Emerging Technologies” Biology Department colloquium at Florida State University. September 8^th, 2016
46. “AAV- mediated retinal gene therapy: Where we are and where we’re going”- The Scripps Research Institute, Jupiter, FL- August 12^th, 2016
47. “AAV-mediated gene therapy for inherited retinal disease”. Research in Progress Seminar Series, University of Florida. March 18^th, 2016.
48. “Future Developments in Gene Therapy”, Public Engagement Day- Retina 2015. Dublin, Ireland, November 7^th, 2015
49. “Gene Therapy for Usher syndrome”. Breakout discussion panel. Retina 2015. Dublin, Ireland, November 7^th, 2015.
50. “Gene Delivery to the Retina: Current and Emerging Technologies”, Scientific Programme- Retina 2015. Dublin, Ireland, November 6^th, 2015
51. “Roadblocks faced developing clinical trials for retinal dystrophies”- ICON PLC, Retina 2015, Dublin, Ireland, November 5^th, 2015
52. “Promoter analysis in support of RPGR XLRP program”- AGTC/Biogen, Gainesville, Fl October 29^th, 2015
53. “AAV-mediated gene therapy for inherited retinal disease”, Foundation Fighting Blindness Jacksonville Chapter Vision Walk Preview Meeting. October 17^th, 2015.
54. “Retinal gene therapy”, Distinguished Lecture Series. Medical College of Wisconsin,  Milwaukee, WI, September 14^th, 2015
55. “Gene Therapy for GUCY2D LCA1” – 2^nd international Retinal Gene Therapy meeting hosted by Casey Eye Institute, Denver, CO, May 2015
56. “Gene therapy 101”- Foundation Fighting Blindness VISIONS conference, Baltimore, MD, June 2015
57. “Gene therapy restores useful vision to a model of the GUCY2D-LCA1 patient fovea, the all-cone Nrl^-/-GC1^-/- mouse”, ARVO, Denver, CO, May 4^th, 2015
58. “Gene Therapy for LCA1, a Summary of Progress”- Genzyme Center, Cambridge, MA (11-3-14)
59. “Gene Therapy 101”- Foundation Fighting Blindness JAX/Orlando chapter meeting. Gainesville, Fl (9-20-14)
60. “Expanding the AAV vector toolkit”- Hope for Vision Conference, Miami, Fl (9-5-14)
61. “AAV-mediated retinal gene therapy, from vector development to clinical application” Casey Eye Institute, OHSU (8-22-14)
62. “Gene replacement in an all cone model of GC1 deficiency‐ focusing in on the affected loci in GUCY2D‐LCA1 patients”. Retinal Degeneration (RD) (7-2014)
63. “Viral Vectors for Retina Research and Therapy”- FASEB Science Research Conference on Retinal Neurobiology and Visual Processing (6-2014)
64. “Gene Therapy 101”- Achromacorp’s Achromatopsia Convention (6-2014)
65. “Gene Therapy 101” – Foundation Fighting Blindness national Visions Conference, Baltimore, MD (6-22-14)
66. “Clinical Trials- Am I Ready?”- Foundation Fighting Blindness national Visions Conference, Denver, CO (6-23-14)
67. “AAV vector gene delivery for treatment of retinal disease”- ARVO, Orlando, FL 5-5-14) Minisymposia
68. “Animal models for pre-clinical studies of gene therapy”- ARVO, Orlando, FL (5-4-14) workshop
69. “Gene Therapy 101”- Foundation Fighting Blindness national Visions Conference, Baltimore MD (6-29-13)
70. “Gene Therapy Clinical Trial Updates”- Foundation Fighting Blindness Visions Conference, Baltimore MD (6-28-13)
71. “Gene Therapy for GUCY2D-Leber Congenital Amaurosis (LCA1)”- Moran Eye Center, University of Utah. Salt Lake City, Utah (5-16-13)
72. “AAV Gene Transfer to the Retina”. Educational symposium. American Society of Gene and Cell Therapy, Salt Lake City, Utah (5-15-2013)
73. “Ocular Gene Therapy: an update and what’s on the horizon”. NIH Gene Therapy Workshop. Bethesda, MA (4-12-13)
74. “Gene Therapy for Photoreceptor-Mediated Retinal Disease: Leber Congenital Amaurosis-1 (LCA1)”. Molecular Genetics and Microbiology Research Conference. University of Florida, Gainesville, Fl (4-30-13)
75. “Update on Gene Therapy for LCA1 and Intravitreal AAV-Mediated therapy for Photoreceptor disease” Research in Progress, Department of Pediatrics. University of Florida, Gainesville, Fl (3-28-13)
76. “Gene Therapy for Photoreceptor-Mediated Retinal Disease: Leber Congenital Amaurosis-1 (LCA1)”. Inherited Retinal Disease: Diagnosis and Therapy Symposium. University of Florida, Gainesville, Fl (10-29-12)
77. “LCA-an overview and preclinical work on the GUCY2D gene”- Foundation Fighting Blindness, The Doctor is In session. Jacksonville, Fl (10-20-12)
78. “Gene Therapy for Inherited Retinal Disease”. Gainesville Lions Club. Gainesville, Fl. (8-6-12).
79. “Gene Therapy for LCA1”- Foundation for Retinal Research (FRR) LCA Family Conference. Philadelphia, PA (7-21-2012)
80. “Gene Therapy for Severe Pediatric Retinal Dystrophy, LCA1”- University of Florida’s Whitney Laboratory. St. Augustine, Fl (7-13-2012)
81. “Gene Therapy for Photoreceptor-Mediated Retinal Disease: Leber Congenital Amaurosis-1 (LCA1)”- University of North Carolina at Chapel Hill (5-22-2012)
82. “Transduction of the Outer Retina”- Ocular Gene Therapy Symposium ARVO. Ft. Lauderdale, Fl (5-6-2012)
83. “Gene Therapy for Photoreceptor-Mediated Disease- Leber Congenital Amaurosis-1 (LCA1)”- Medical University of South Carolina (MUSC), Storm Eye Institute, Charleston, SC (4-2-12)
84. “Gene Therapy for LCA1 (Guanylate Cyclase Deficiency) in Mouse Models”- University of Florida’s Department of Ophthalmology 50^th anniversary celebration, Gainesville, Fl (3-23-12)
85. “The Other LCA” Powell Gene Therapy Center, University of Florida. Gainesville, Fl (10-13-10)
86. “Gene Therapy Restores Function to Cone Cells in An Animal Model of Leber Congenital Amaurosis (LCA-1)” Whitney Laboratory- St. Augustine, Fl (06-16-06)

Meetings Organized:

• Organizer of the Foundation Fighting Blindness Jacksonville and Orlando chapters’ “Gene Therapy 101” visit to UF (9-20-14)
• Co-organizer of Achromacorp’s Achromatopsia convention (June 6-7, 2014). Co-organizer with Dr. Christine Kay and Bridget Vissari (CEO of Achromacorp). This meeting featured on Yahoo Finance.
• Co-organizer along with Drs. Clay Smith and Christine Kay of the University of Florida’s Center for Vision Research 2012 annual symposium entitled “Inherited Retinal Disease”